Interestingly, in neuroblastoma, Balamuth et al. (2010) identified increased expression of Lgr5 (Gpr49) as a potential therapeutic target and marker of disease in the murine TH-MYCN neuroblastoma model and in human MYCN amplified neuroblastomas (Balamuth et al., 2010). Here, LGR5 is linked to neuroblastoma.